Welcome Guest
Home » Press Releases » NASH drugs market could be worth USD 30 billion, predicts Roots Analysis

NASH drugs market could be worth USD 30 billion, predicts Roots Analysis


Published : Oct 01, 2015

Roots Analysis has announced the addition of “NASH Drugs Market, 2015-2025” report to their offering. The study offers a comprehensive analysis of the current landscape and future outlook of the evolving pipeline in this area. While the field has garnered interest of several companies, there are still no approved therapies. It is important to stress that the development pipeline has several promising candidates that are likely to result in commercial success stories in foreseen future.

 

Ishita Nanda, the principal analyst, said, “Amongst other elements, the report elaborates on the new diagnostic solutions being developed and the upcoming opportunities for different stakeholders. As pharmaceutical companies continue to initiate and expand their research programs in this area, one of the key objectives outlined for this report is to understand the future market potential. This is done by analyzing:

  • The epidemiology, patient population and staging of NASH in different geographies.
  • The NASH pipeline in terms of phase of development, type of molecule, route of administration and mechanism of action.
  • The likely evolution in the rate of diagnosis, drug treated patient population and the likely price of the drugs.
  • The associated constraints, in terms of undefined pathogenesis and the unavailability of non-invasive diagnostic tests, and the initiatives being carried out by companies to overcome these.”

 

Nanda added, “Our opinions and insights were influenced by the discussions we held with experts in this area. These included senior representatives at BiOrion Technologies, Phenex Pharmaceuticals, Tobira Therapeutics, Verlyx Pharmaceuticals and Connexios. Recognizing the huge unmet medical need, several companies are striving to establish an early foothold in the market.”

 

The 188 page report includes detailed profiles and an assessment of the clinical research pipeline of many companies mentioned below.

  • Intercept Pharmaceuticals
  • Conatus Pharmaceuticals
  • Genfit
  • Tobira Therapeutics
  • Galmed Pharmaceuticals
  • Gilead Sciences
  • Galectin Therapeutics
  • Islet Sciences
  • Raptor Pharmaceuticals
  • Zydus Cadila

 

Several other companies (mostly start-ups), which have molecules in early stages of development, have also been covered. Examples of such companies include Cerenis Therapeutics, DS Biopharma, Immuron, Matinas BioPharma, Metabolic Solutions, Naia Pharmaceuticals, Nimbus Therapeutics, Verva Pharmaceuticals, ViroBay and Zafgen. This study is targeted towards research groups working in the field of liver disorders. For additional details, please visit 

http://www.rootsanalysis.com/reports/view_document/nash-drugs-market-2015-2025/107.html

 

or email This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 

 

About Roots Analysis

 

Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like us to help you with your growing business needs, get in touch at This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 

 
Copyright © Roots Analysis. All Rights Reserved.
website security